G. Carter

Statistics

Publications

Citations

149

H-Index

Active since

2016

Affiliations

Eli Lilly (United States)(Current)

G. Carter is an author at Eli Lilly (United States) specializing in antidepressant efficacy, antidepressant therapy, and antidepressant pharmacotherapy.

Publications per year

2016–2017

Publications

The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits

J M Witkin, James A. Monn, Darryle D. Schoepp et al. · Journal of Pharmacology and Experimental Therapeutics · 2016 · 106 citations

Medicine, Neuroscience, Pharmacology +17

Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression.

Jeffrey M. Witkin, S.N. Mitchell, Keith A. Wafford et al. · Journal of Pharmacology and Experimental Therapeutics · 2017 · 43 citations

Medicine, Pharmacology, Pharmacotherapy +17

1–2 of 2